- Email: [email protected]
5173415 Process for removal of viruses from solutions of physiologically active substances
364
PATENT ABSTRACTS
parasite or other whole microorganism. The complex of antigen coupled to antibody may be used in immunizing a higher animal against an antigen.
biological fluids, using a monoclonal antibody mixture. The present invention further provides methods for the use of these monoclonal antibodies for the detection of anti-HIV-1 p24 antibodies and HIV-2 p24 antigen in biological samples.
5173294 DNA PROBE FOR THE IDENTIFICATION OF HAEMOPHILUS INFLUENZAE Timothy F Murphy, Michael A Apicella assigned to Research Foundation of State University of New York A plasmid which contains a genetic code for an immunogenic portion which is conserved in many strains of nontypable Haemophilus influenzae and the bacterium containing this plasmid is disclosed. The immunogenic portion is preferably an epitope on an outer membrane protein of H. influenzae. A monoclonal antibody to the immunogenic portion and the hybridoma which will produce the monoclonal antibody is also included. The invention further includes a D N A probe constructed to correspond to the nucleic acids which code for the immunogenic portion. This probe may be labelled with a radioactive marker and may be used as a diagnostic tool to assay various clinical samples for the presence of H. influenzae.
5173399 MOUSE MONOCLONAL ANTIBODIES TO HIV-IP24 AND THEIR USE IN DIAGNOSTIC TESTS Smriti U Mehta, Jeffrey C Hunt, Sushil G Devare assigned to Abbott Laboratories The present invention provides monoclonal antibodies demonstrating specific reactivity with HIV-1 p24. One monoclonal antibody designated 31-42-19 recognizes an unique epitope on HIV-I p24 that is not immunogenic in humans. 31-42-19 also reacts with an antigenicaUy cross reactive epitope on HIV-2 p24. Another monoclonal antibody designated 3190-25 recognizes an epitope within a highly immunogenic region of HIV-I p24. The present invention also provides cell lines capable of producing these monoclonal antibodies. The invention also includes a highly sensitive enzyme immunoassay for the detection of HIV-I p24 in
5173415 PROCESS FOR REMOVAL OF VIRUSES FROM SOLUTIONS OF PHYSIOLOGICALLY ACTIVE SUBSTANCES Hajim Hiratani, Jun Tateishi, Tetsuyuki Kitamoto, Sennan, Japan assigned to Japan Chemical Research Co Ltd A membrane filter of 0.025 to 0.05 mu in pore size is treated by passing the solution of a watersoluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, gelatin or the like through the membrane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hormone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active substance can be removed.
5173420 MONOCLONAL ANTIBODY RECOGNIZING UN-NATURAL GANGLIOSIDE GD3 Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto, Kyoto, Japan assigned to MECT Corporation A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrow9NeuAc terminal. A monoelonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrowfGal beta terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc alpha2 right arrow9NeuAc terminal, NeuAc alpha2 right arrow6Gal beta terminal and NeuAc
PATENT ABSTRACTS
parasite or other whole microorganism. The complex of antigen coupled to antibody may be used in immunizing a higher animal against an antigen.
biological fluids, using a monoclonal antibody mixture. The present invention further provides methods for the use of these monoclonal antibodies for the detection of anti-HIV-1 p24 antibodies and HIV-2 p24 antigen in biological samples.
5173294 DNA PROBE FOR THE IDENTIFICATION OF HAEMOPHILUS INFLUENZAE Timothy F Murphy, Michael A Apicella assigned to Research Foundation of State University of New York A plasmid which contains a genetic code for an immunogenic portion which is conserved in many strains of nontypable Haemophilus influenzae and the bacterium containing this plasmid is disclosed. The immunogenic portion is preferably an epitope on an outer membrane protein of H. influenzae. A monoclonal antibody to the immunogenic portion and the hybridoma which will produce the monoclonal antibody is also included. The invention further includes a D N A probe constructed to correspond to the nucleic acids which code for the immunogenic portion. This probe may be labelled with a radioactive marker and may be used as a diagnostic tool to assay various clinical samples for the presence of H. influenzae.
5173399 MOUSE MONOCLONAL ANTIBODIES TO HIV-IP24 AND THEIR USE IN DIAGNOSTIC TESTS Smriti U Mehta, Jeffrey C Hunt, Sushil G Devare assigned to Abbott Laboratories The present invention provides monoclonal antibodies demonstrating specific reactivity with HIV-1 p24. One monoclonal antibody designated 31-42-19 recognizes an unique epitope on HIV-I p24 that is not immunogenic in humans. 31-42-19 also reacts with an antigenicaUy cross reactive epitope on HIV-2 p24. Another monoclonal antibody designated 3190-25 recognizes an epitope within a highly immunogenic region of HIV-I p24. The present invention also provides cell lines capable of producing these monoclonal antibodies. The invention also includes a highly sensitive enzyme immunoassay for the detection of HIV-I p24 in
5173415 PROCESS FOR REMOVAL OF VIRUSES FROM SOLUTIONS OF PHYSIOLOGICALLY ACTIVE SUBSTANCES Hajim Hiratani, Jun Tateishi, Tetsuyuki Kitamoto, Sennan, Japan assigned to Japan Chemical Research Co Ltd A membrane filter of 0.025 to 0.05 mu in pore size is treated by passing the solution of a watersoluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, gelatin or the like through the membrane filter. Employing the filter thus treated, the solution of a physiologically active substance of human origin such as human growth hormone, kallikrein, trypsin inhibitor, epidermal growth factor, leucocyte interferon etc. is filtered at high recovery rate of the active substance avoiding the adsorption of the active substance onto the filter. By the filtration, harmful viruses such as Creutzfeldt-Jacob disease pathogen which may exist in the physiologically active substance can be removed.
5173420 MONOCLONAL ANTIBODY RECOGNIZING UN-NATURAL GANGLIOSIDE GD3 Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto, Kyoto, Japan assigned to MECT Corporation A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrow9NeuAc terminal. A monoelonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc alpha2 right arrowfGal beta terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc alpha2 right arrow9NeuAc terminal, NeuAc alpha2 right arrow6Gal beta terminal and NeuAc